I am a healthcare professional in the UK
I am a patient or member of the public
EBMT 2024 Highlights
2 minutes
EBMT 2024 Highlights
Summary of highlights from EBMT 2024 in Glasgow, Scotland, 14-17 April from Sr Angela Leather and Dr Bhuvan Kishore.
Section 1: Presented at EBMT 50th Annual Meeting 14th to 17th April 2024.
Papanicolaou et al - Sr Angela Leather
Abstract A181 – Papanicolaou et al. MULTINATIONAL STUDY ASSESSING TREATMENT PATTERNS, OUTCOMES, AND HEALTHCARE RESOURCE UTILIZATION IN HEMATOPOIETIC STEM CELL TRANSPLANT RECIPIENTS WITH CYTOMEGALOVIRUS INFECTION AND INTOLERANCE TO ANTICYTOMEGALOVIRUS THERAPIES Poster presentation by Martha Fox at EBMT 50th Annual Meeting 14th to 17th April 2024.
Maertens et al - Dr Bhuvan Kishore
P122- Maertens et al. Real world outcomes and treatment patterns of CMV infections in HSCT recipients who are refractory or intolerant to treatments.
See Bhuvan and Angela discuss these first two presentations in the video below.
Brightcove Video
Section 2: Presented at EBMT 50th Annual Meeting 14th to 17th April 2024.
Zamora et al - Dr Bhuvan Kishore
OS11-02 - Zamora et al Analysis of Pre-transplantation CMV-specific humoral immunity as a predictor for CMV reactivation after HSCT using VIRSCAN serologic profiling and pentameric complex-specific neutralisation.
Duplessix et al - Dr Bhuvan Kishore
OS11-07 - Duplessix et al CMV specific T-Cell activity determines the risk of clinically significant CMV reactivation following letermovir prophylaxis after allogeneic-HSCT.
See Bhuvan and Angela discuss the Zamora and Duplessix presentations in the video below
Brightcove Video
Section 3: Presented at EBMT 50th Annual Meeting 14th to 17th April 2024.
Maiers, M et al - Sr Angela Leather
OS2-08 Maiers, M et al AN AI MODEL TO OPTIMIZE DONOR SELECTION USING A CONTEMPORARY DATASET Oral presentation.
Descamps et al - Sr Angela Leather
Abstract NG20-04 - Descamps et al PATIENTS' PERSPECTIVES ON PSYCHOSOCIAL SUPPORT IN ALLOGENEIC STEM CELL TRANSPLANTATION WITH A RELATED DONOR Oral presentation by Lotte Kinds (Finalist for research abstract - Nurse group).
See Bhuvan and Angela discuss the Maiers & Descamps presentations in the video below.
Brightcove Video
Section 4: Presented at EBMT 50th Annual Meeting 14-17 April 2024
Gagelmann et al - Dr Bhuvan Kishore
OS15-01 - Gagelmann et al Daratumumab for PRCA after HSCT: A study from the transplant complications working party of EBMT.
See Bhuvan and Angela discuss the Gagelmann et al presentation in the video below.
Brightcove Video
The content from EBMT 2024 is created independently of Takeda.
You might be interested in
1 minute
download
This concise guide to LIVTENCITY® (maribavir) is designed for clarity and ease of use. It summarises key insights from the Phase 3 SOLSTICE trial, including efficacy outcomes, safety data, and practical dosing guidance.
article
6 minutes
A summary of the safety profile of LIVTENCITY, including adverse event data and tolerability findings from clinical studies.
article
3 minutes
CMV is one of the most common infections experienced by transplant recipients
article
4 minutes
An overview of the pivotal Phase 3 SOLSTICE trial, outlining the study design, patient population, and methodology that underpin the clinical evidence for LIVTENCITY.
